-
Clinical Trials & Development2 months agoRoche sweeps neurology corporate reputation rankings once again
Roche has retained its status as the neurology drugmaker that patient groups hold in the highest esteem, once again completing a clean sweep of PatientView’s corporate...
-
Clinical Trials & Development2 months ago
Novartis’ centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
The phase 3 Harbor trial of Novartis’ del-desiran has missed its primary endpoint, dealing a major blow to an asset that the Swiss drugmaker acquired in...
-
Clinical Trials & Development2 months ago
Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability
Inhibrx Biosciences’ CEO has argued that the 9.6 months of progression-free survival demonstrated by its OX40 agonist in a phase 2 study has proven the therapy’s...
-
Clinical Trials & Development2 months ago
Novo Nordisk STEP Young Phase 3 Data: 40.4% of Children Living with Obesity Achieved a BMI Below the Obesity Threshold with Semaglutide and Lifestyle Modification
Bagsværd, Denmark, 7 September 2026 – Novo Nordisk today announced first results from the STEP Young phase 3 trial, evaluating once-weekly semaglutide in combination with a...
-
Clinical Trials & Development2 months ago
When every treatment counts: How clinical trials are changing the outlook for non-Hodgkin lymphoma patients
Discover Andy Brown's long and arduous journey battling a type of non-Hodgkin lymphoma and how a clinical trial altered his treatment outlook. The post When every...
-
Clinical Trials & Development2 months agoNovartis hit as Lp(a) drug fails cardio outcomes trial
Novartis shares have slipped after it revealed its Lp(a)-targeted drug, pelacarsen, failed to reduce cardiovascular risks in a major phase 3 trial.
-
Clinical Trials & Development2 months ago
Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped
Novo Nordisk has given up on two more phase 3 trials of ziltivekimab, further eroding the prospects for a molecule that analysts had once tipped as...
-
Clinical Trials & Development2 months agoIntegration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment
Nature Biotechnology, Published online: 07 September 2026; doi:10.1038/s41587-026-03286-ySix proteomic clocks are applied in a clinical trial to assess anti-aging effects.
-
Clinical Trials & Development2 months agoEmotional Changes in Chronically Ill Patients After a Complementary Therapy Support Program
When patients living with long-term illnesses such as cancer, diabetes, or chronic pain walk through the doors of a hospital workshop dedicated to painting, music, relaxation,...
-
Clinical Trials & Development2 months agoTreating osteoporosis in older men: review of drug and lifestyle trials
Osteoporosis has long been framed as a disease of older women, but a new systematic review of randomized controlled trials is drawing attention to a population...
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
